NCT00482495View on ClinicalTrials.gov

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

November 30, 2009

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

bevacizumab

GENETIC

gene expression analysis

GENETIC

protein expression analysis

OTHER

laboratory biomarker analysis

Trial Locations (1)

55940

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER